contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


senzime-publishes-prospectus-in-connection-with-the-listing-on-nasdaq-stockholm

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Senzime

Uppsala, 24 June 2021. On 23 June 2021, Senzime AB (publ) announced that Nasdaq Stockholm’s Listing Committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm...

<div class="mfn-preamble"><p><strong>Uppsala, 24 June 2021. On 23 June 2021, Senzime AB (publ) announced that Nasdaq Stockholm’s Listing Committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market, conditioned upon customary conditions being fulfilled. The prospectus prepared in connection with the listing has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Senzimes website www.senzime.com and will be made available on the Swedish Financial Supervisory Authority’s website www.fi.se.</strong></p></div><div class="mfn-body"><p>Link to prospectus (only available in Swedish): [<a rel="nofollow noopener" href="https://senzime.com/wp-content/uploads/2021/06/Prospekt-2021-Senzime-AB-publ-final-version.pdf">Prospectus Senzime AB 2021</a>]</p><p>The first day of trading on Nasdaq Stockholm’s main market is scheduled for Wednesday 30 June 2021 and the last day of trading on Nasdaq First North Growth Market is scheduled for Tuesday 29 June 2021. The shares will be traded under the same ticker (SEZI) and ISIN-code (SE0002478776). There is no offering or issue new shares in connection with the list change, and shareholders in Senzime do not need to take any actions.</p><p>Advokatfirman Lindahl has acted as legal advisor in connection with the listing on Nasdaq Stockholm.</p><p><em>N.B. English translation is for convenience purposes only.</em></p></div><div class="mfn-footer mfn-"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Pia Renaudin, CEO of Senzime AB&nbsp;<br>Phone: +46 (0) 70-813 34 17, e-post:&nbsp;<a rel="nofollow noopener" href="mailto:pia.renaudin@senzime.com">pia.renaudin@senzime.com</a><br>&nbsp;<br>Erik Bergman, CFO<br>Phone: +46 (0) 73-258 81 59, e-mail: <a rel="nofollow noopener" href="mailto:erik.bergman@senzime.com">erik.bergman@senzime.com</a></p></div><div class="mfn-footer mfn-about"><p><strong class="mfn-heading-1">About Senzime</strong></p><hr><p>Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00&nbsp;399,&nbsp;<a rel="nofollow noopener" href="mailto:info@fnca.se">info@fnca.se</a>&nbsp;is Certified Adviser for Senzime.&nbsp;<a rel="nofollow noopener" href="http://www.senzime.com/">www.senzime.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/67d2848b-28b9-42c4-ae46-cee8376d0d47/senzime-publishes-prospectus-in-connection-with-the-listing-on-nasdaq-stockholm.pdf" class="mfn-generated mfn-primary">SENZIME PUBLISHES PROSPECTUS IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM</a></p></div>

SENZIME PUBLISHES PROSPECTUS IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation